TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~For both step I and II:~* Patients with histologically confirmed squamous cell carcinoma of the anal canal~* Aged 18 years or older~* ECOG: 0-1-2~* Adequate contraception in women of child-bearing potential and for men~* Ability to understand and the willingness to sign a written informed consent document.~* HIV-positive patients with T1-2 anal canal tumors, or~* Patients with anal canal tumors not eligible for conventional chemotherapy (for example, due to age and/or co-morbidities)~* Patients who have already started radiotherapy for anal canal cancer~For step II:~* HIV-positive patients with T1, T2 anal canal tumors~* HIV-negative patients not eligible for conventional chemotherapy (for example, due to age and/or co-morbidities)~* HIV-negative patients with T1-2 anal canal cancer~Exclusion Criteria:~For both step I and II:~* Patients receiving any other investigational agents~* Previous treatment with anti-EGFR drugs~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nimotuzumab or other agents used in study.~* Previously treated with pelvic radiotherapy.~* Lesions not suitable for radiotherapy~* Patients with uncontrolled hypercalcemia~* Uncontrolled intercurrent illness~* Pregnant or breast-feeding women~* Any concurrent active malignancy~* Patients with T3-4 anal canal tumors or patients with nodes positive.~Step I:~* HIV-negative patients with anal canal tumors that are judged suitable for current treatment consisting in radiotherapy and 5-FU and MMC chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nimotuzumab (Type: EXPERIMENTAL): Patients will receive weekly injections of Nimotuzumab (200mg/injection) for 12 weeks and standard external beam radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiofrequency Ablation in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Breast single tumor,~* Clearly visible by ultrasound,~* Diameter \< 2 cm~* Located \>1 cm from the chest wall and skin;~* Ductal carcinoma according to previous biopsy,~* \< 20% of intraductal carcinoma~Exclusion Criteria:~* Breast cancer in men;~* Personal history of ipsilateral breast cancer;~* Age \<40 years;~* Pregnancy or breastfeeding;~* Suspicion of intraductal extension or multifocality by mammography or MRI;~* Tumour not visible by ultrasound;~* Diameter \> 2 cm;~* Distance to muscle or skin \<1 cm;~* Lobular carcinoma;~* Intraductal carcinoma in \> 20% of the biopsy sample~* Patients undergoing neoadjuvant chemotherapy or hormonotherapy.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RFA group (Type: EXPERIMENTAL): A percutaneous (utlrasound-guided) radiofrequency ablation (RFA) of the tumor will be performed by the radiologist under general anesthesia. Immediately after, excision of the tumor with appropriate margin will be accomplished.
- Control group (Type: NO_INTERVENTION): Normal excision of the tumor according to the protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Management of Signs and Symptoms Associated With Dry Eye Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with moderate dry eye defined as corneal fluorescein staining score of ≥ 3~* Age ≥ 18 years~* Distance best corrected visual acuity better than 20/60 Snellen equivalent in each eye~* Willing to sign a written informed consent to participate~* Able to follow study instructions, with the intention of completing all required visits~Exclusion Criteria:~* Presence of persistent corneal epithelial defect or ulcer in either eye~* Presence of active ocular infection in either eye~* Presence of ocular inflammation that is not related to keratoconjunctivitis sicca, e.g., allergy, severe blepharitis~* Presence of other corneal disorder(s) that give rise to reduced corneal sensitivity, such as recurrent herpes keratitis~* Presence of corneal diseases other than dry eye that can disturb the pre-corneal tear film such as epithelial basement membrane dystrophy (EBMD)~* Contact lens wear~* History of recent ocular surgery/trauma, which could affect corneal sensitivity, e.g., corneal transplantation, LASIK~* Presence of cicatricial ocular surface diseases~* A medical or ocular condition, or a personal situation, which in the principal investigator's opinion, is not appropriate for participation in the trial~* Any scheduled or planned ocular or systemic surgery or procedure during the study~* Pregnancy and women who are expecting to be pregnant.~* Current enrolment in another interventional drug or device study or participation in such a study within 30 days of anticipated entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): PROKERA SLIM + Standard of Care
- Control Arm (Type: ACTIVE_COMPARATOR): Standard of Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Lupus.~* Able and willing to have blood drawn for PK sampling.~Exclusion Criteria:~* Have severe active lupus nephritis.~* Have severe active central nervous system (CNS) or peripheral neurologic disease or other severe neurologic involvement requiring treatment within approximately 3 months prior to screening.~* Have received high dose corticosteroid within approximately 1 month prior to baseline.~* Have initiated or adjusted treatment with immunosuppressant drugs within approximately 1 month prior to baseline.~* Have received plasmapheresis within approximately 3 months prior to baseline.~* Have previously received approved or experimental B cell targeted therapies within the last year.~* Have received any biologic or non-biologic therapy within approximately 3 months or 5 half-lives (whichever is longer).~* Have a history of severe reaction to any biologic therapy.~* Have an active or recent infection within approximately 1 month prior to Week 0.~* Have had a serious infection within approximately 3 month or serious bone/joint infection within approximately 6 months prior to baseline.~* Have evidence of or test positive for active hepatitis B or are positive for hepatitis C or human immunodeficiency virus (HIV).~* Have evidence of active or latent tuberculosis.~* Have significant hematological abnormalities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tabalumab Auto-Injector (Type: EXPERIMENTAL): Tabalumab given Week 0 as a loading dose of 240 milligram (mg) given as two subcutaneous (SC) injections each of 120 mg followed by 120 mg SC injection every two weeks for 12 weeks. Participants may continue on this treatment regimen for 52 weeks.
- Tabalumab Prefilled Syringe (Type: EXPERIMENTAL): Tabalumab given Week 0 as a loading dose of 240 mg given as two SC injections each of 120 mg followed by 120 mg SC injections every two weeks for 12 weeks. Participants may continue to on this treatment regimen for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Proton Radiation Therapy in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed prostate adenocarcinoma within 365 days of registration~* Clinical stages T1a-T2a N0 M0~* For any pelvic lymph node \>= 1.5cm, biopsy of the lymph node is mandatory~* Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason score must be in the range 2-6; \> 6 cores is strongly recommended; the highest Gleason score in any core reported on the pathology report will be used for determining inclusion~* PSA values \< 10 ng/ml within 90 days prior to registration, done either prior to prostate biopsy or at least 21 days after prostate biopsy.~* Alkaline phosphatase within 60 days prior to registration. If alkaline phosphatase is elevated \> 2 x the upper limit of institutional normal (UNL), patient must have radiological correlation to assess for metastases~* Zubrod status 0-1 documented within 60 days of registration~* Prior androgen deprivation is allowed; however, androgen deprivation will not be continued concurrently or as an adjuvant therapy~* Patients must give IRB-approved study-specific informed consent~* Patients must complete all required tests listed within the specified time frames~* Patients must be able to start treatment within 56 days of registration~* Members of all races and ethnic groups are eligible for this trial~Exclusion Criteria:~* Clinical stages T2c or greater~* PSA of 10 ng/ml or greater~* Gleason score 7 or higher~* Evidence of distant metastasis~* Evidence of lymph node involvement~* Previous prostate cancer surgery to include: prostatectomy, hyperthermia and cryosurgery~* Previous pelvic radiation for prostate cancer~* Androgen deprivation therapy prior to radiation is allowed; however, it is not acceptable if continued during radiation or as adjuvant therapy~* Active rectal diverticulitis, Crohn's disease, or ulcerative colitis are not allowed~* Prior systemic chemotherapy for prostate cancer~* History of proximal urethral stricture requiring dilatation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients undergo proton radiotherapy once daily 5 days a week for approximately 9 weeks in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Music Therapy for Spontaneous Breathing Trials

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18+~* Admitted to MUSC's Main Hospital medical intensive care unit (MICU) or Ashley River Tower medical-surgical intensive care unit (MSICU)~* Intubated and will undergo a spontaneous breathing trial~Exclusion Criteria:~* Patients who have had any prior SBTs~* Patients known to have a neurological injury~* Patients who are known to be deaf~* Patients whom (or whose LAR) are unable or unwilling to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Music Therapy plus Standard Care (Type: EXPERIMENTAL): Music therapy intervention in addition to standard hospital care during an SBT.
- Standard Care (Type: ACTIVE_COMPARATOR): Standard hospital care during an SBT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Peripheral I.V. Catheter Complication Rates of Two Different Catheter Dressings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. At least 18 years of age, or of consenting age;~2. Admitted or going to be admitted to the hospital;~3. Requires peripheral IV therapy (catheter) for an anticipated 72 hours or longer;~4. Has an insertion site in the forearm or hand free of phlebitis, infiltration, dermatitis, burns, lesions or tattoos;~5. Demonstrates cooperation with a catheter insertion and the securement protocol; and~6. Patient or legally authorized representative is willing and able to provide written informed consent and authorization for use and disclosure of Protected Health Information~Exclusion Criteria:~1. Is a current participant or a past participant in this study;~2. If the subject already has a functioning PIV in place, not requiring a replacement catheter~3. If the study PIV catheter site will be placed below an old infusion site;~4. If the study PIV site needs to be immobilized with a splint or other device;~5. Has a documented or a known allergy or sensitivity to a medical adhesive product such as transparent film adhesive dressings, tapes, or liquid skin protectants;~6. Requires the application of a gauze pad, a topical ointment or solution under the dressing in addition to the prep(s) required in the protocol;~7. Will require a power injection through the study PIV catheter for a radiologic procedure during participation in this study;~8. Will require a numbing agent prior to PIV insertion; or~9. Will require the use of ultrasound for the PIV catheter insertion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- New PIV Dressing (Type: EXPERIMENTAL): Bordered, notched dressing that covers, secures peripheral intravenous (PIV) catheter
- Standard PIV Dressing (Type: OTHER): Film,adhesive dressing that covers, secures peripheral intravenous (PIV) catheter and used with a medical grade tape

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: LXRA Gene Polymorphisms and Response to Fenofibrate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Triglycerides equal to or above 150mg/dL or Low HDL (below 44 mg/dl for men or below 54 mg/dl for women)~* Must be able to swallow tablets~Exclusion Criteria:~* Known Coronary Heart Disease, symptomatic carotid artery disease, abdominal aortic aneurysm, diabetes, or Framingham risk score above 20%~* Pregnancy, malignancy, liver dysfunction, renal dysfunction, active alcohol abuse, history of unexplained muscle pain~* Current treatment with lipid lowering therapy, estrogens, androgens, progestins, thiazide diuretics, beta-blockers, glucocorticoids (other than inhaled), antihistamines, or chronic anti-inflammatory drugs~* Current treatment with the following the interacting drugs: ursodeoxycholic acid, ursodiol, cholestyramine, red yeast rice, glyburide, glipizide, warfarin, or cyclosporine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1-Fenofibrate then Placebo (Type: ACTIVE_COMPARATOR): 4 weeks of drug at 160 mg orally per day, 4 week washout, then 4 weeks of placebo
- 2 Placebo then Fenofibrate (Type: ACTIVE_COMPARATOR): 4 weeks of placebo then 4 week washout then 4 weeks of Fenofibrate at 160 mg/day orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive-Behavioral and Physical Activity Interventions for Binge Eating and Overweight

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 to 65 years old;~2. Meet DSM-5 criteria for BED or BED but without the size criterion (LOC eating);~3. BMI 25-45 kg/m2;~4. Sedentary activity pattern (\< 90 mins/week of moderate-to-vigorous intensity recreational physical activity);~5. Available for the duration of the treatment and follow-up (7 months);~6. Read, comprehend, and write English at a sufficient level to complete study-related materials.~Exclusion criteria:~1. Co-existing psychiatric condition that requires hospitalization or more intensive treatment (e.g., bipolar mood disorders, psychotic illnesses, severe depression).~2. Reports active suicidal or homicidal ideation.~3. Current anorexia or bulimia nervosa.~4. Contraindications to physical activity.~5. Blood pressure \>140 systolic or \>90 diastolic.~6. Breast-feeding or pregnant, or planning to become pregnant during the study.~7. History of stroke or myocardial infarction.~8. Current or recent (within 12 months) drug or alcohol dependence~9. Currently receiving effective treatment for eating or weight loss.~10. Currently participating in another clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cognitive-Behavioral Therapy (Type: EXPERIMENTAL): Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Taurolidin on Prevention of Bloodstream Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age superior to 18 years~* Home parenteral nutrition on tunnelized central venous catheters~* Bloodstream infection confirmed by differential hemocultures~* Informed consent form signed~* Negative B-HCG test~Exclusion Criteria:~* Subject unable to give his informed consent~* Pregnancy~* Subject who have a two or three-way catheter, or a non-tunnelized central venous catheter~* Hospital related infection~* Central venous catheters placed since less than 15 days~* Neutropenia \< 500 PNN/mm3~* Fungal Infection, polymicrobial who need ablation of the central venous catheters~* No-response to clinical treatment of the Infection~* Septic thrombophlebitis~* Chemotherapy ongoing~* On going malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Use of taurolidine in prevention of bloodstream infection related to central venous access
- B (Type: PLACEBO_COMPARATOR): Use of Physiologic Serum to compare to arm A

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men or women age ≥18 years~* Histologically confirmed metastatic (stage IV) adenocarcinoma of the pancreas~* Measurable disease defined per RECIST~* Karnofsky Performance Status ≥50~* Expected survival ≥12 weeks~* Provide written informed consent~Exclusion Criteria:~* CNS metastases~* Prior treatment with other chemotherapy for pancreatic cancer unless used as a radiosensitizer~* Radiation therapy to \>25% of the bone marrow~* Clinically significant laboratory abnormalities~* Any malignancy within the 5 years immediately prior to the first dose of study medication with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix~* The need for chronic (i.e., \>7 days) oral or intravenous corticosteroid therapy with \>10mg/day prednisone equivalents~* Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol~* Patients who are within 28 days of radiation therapy, biologic therapy, immunotherapy, or other investigational medication. All side effects of prior treatment must have resolved at study entry.~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval